OsteoCool™ 2.0 Radiofrequency ablation system

The OsteoCool™ 2.0 system combines internally-cooled radiofrequency (RF) ablation probes with a 100W generator and simultaneous, four-probe capability to palliatively treat painful bone tumors.

About the therapy

Alert Indications, Safety, and Warnings

Overview

Product details

The OsteoCool™ 2.0 RF ablation system helps you deliver optimal care for your patients – faster. OsteoCool™ 2.0 ablates up to 30% faster than OsteoCool™ 1.0,^1,† supports the use of four probes simultaneously, and delivers a market-leading 20W of power per channel.^2-4

Independent channel control allows you to start and stop ablation on each channel individually, while internally-cooled probes reduce the risk of charring without introducing ionic solutions into the ablation.

With the widest selection of probe sizes^2-4 and OsteoMap™ technology, OsteoCool™ 2.0 provides consistent, predictable ablation zones with the flexibility to tailor the ablation zone to your patients' needs. Backed by OPuS One⁵, the largest study of RF ablation in bone metastases, the OsteoCool™ 2.0 RF ablation system gives you the control to deliver powerful, predictable, and proven pain relief.

Download the product brochure

Image from breast cancer case study with Dr. Levy.

Image courtesy of Dr. Jason Levy

OsteoCool™ hard bone access kit

The Medtronic bone access toolkit includes a tapered cannula, sharper trocar, and enhanced drill design – a system that allows improved access to sclerotic bone. These tools are compatible with the existing OsteoCool™ RF ablation probes.

The tools:

- Offer faster access to sclerotic bone^6†
- Reduce the force required to advance the tool^6†
- Are versatile for use for all cases

Download the brochure

Talk to a Medtronic representative to learn more about OsteoCool™ 2.0

* Indicates a required field.

I agree to receive email information and updates from Medtronic.*

I have read and agree with the use of my personal data, including my sensitive data, required for this service as described in the Privacy Notice*.

I have read and agree with the other Terms and Conditions* associated with this service.

† Bench testing may not be indicative of clinical results

Based on internal data: ETR 30101200, OsteoCool 2.0 Lesion Validation Test Report, 20 samples. 2023.

Clarivate Interventional Oncology Devices Market Insights United States report, December 2022.

Stryker OptaBlate™ RF Generator System IFU 700001075365 Rev-AC.

⁴

Merit MetaSTAR™ RF Generator IFU 403321001_001.

⁵

OPuS One. Levy J, David E, Hopkins T, et al. Radiofrequency Ablation Provides Rapid and Durable Pain Relief for the Palliative Treatment of Lytic Bone Metastases Independent of Radiation Therapy: Final Results from the OsteoCool Tumor Ablation Post-Market Study. Cardiovasc Intervent Radiol. 2023;46(5):600-609.

⁶

Medtronic data on file: ETR 31101395, Repetitive Impact and Axial Compression Bench Testing, N=6 of each tool tested. January 2023.